Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of RotaTeq at Expiry Potency
NCT00092443Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2002
- Primary completion
- Jun 2004
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in rotavirus gastroenteritis comparing RotaTeq with Placebo (2 arms). Primary endpoint: Occurrence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine. Started Sep 2002; status: completed.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT00092443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092443.